Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06750471 · ClinicalTrials.gov registry record · Phase 4
Dupixent Study for Alternate Administration
A Phase 4 study of Chronic Disease and Sinusitis, sponsored by Madigan Army Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06750471: Active Phase 4 study of Chronic Disease and Sinusitis, sponsored by Madigan Army Medical Center.
NCT06750471 is a Phase 4 study of Chronic Disease and Sinusitis that is active but no longer recruiting, run by Madigan Army Medical Center. The registered enrollment target is 30 participants, below the 89,943-participant average among 48 other Chronic Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06750471, a Phase 4 study of Chronic Disease and Sinusitis, is active but no longer recruiting, sponsored by Madigan Army Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if the alternate schedule of drug administration is non-inferior in both subjective and objective outcomes.
Primary Outcome
22 item questionnaire of impact of chronic rhinosinusitis on quality of life. Scored from 0-120: higher number = worse symptoms
Conditions Studied
Interventions
- BIOLOGICAL Dupilumab
Study Locations (1)
Washington
- Madigan Army Medical Center - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What the registry record for NCT06750471 still lists
NCT06750471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 89,943-participant average among 48 other Chronic Disease trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Chronic Disease appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT06750471 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06750471 about?
NCT06750471 is a clinical study titled "Dupixent Study for Alternate Administration". Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if ...
What is the current status of trial NCT06750471?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2021-10-14. Estimated completion is 2025-12.
What conditions does trial NCT06750471 study?
This clinical trial studies the following conditions: Chronic Disease, Sinusitis, Nasal Polyps.
What interventions are being tested in trial NCT06750471?
The interventions under investigation include: Dupilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06750471?
This trial is sponsored by Madigan Army Medical Center, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06750471 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06750471's enrollment target sits among peer trials
30 43rd of 48 higher than 5 of 48 other Chronic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Click & Pick Study
RECRUITING · NA
-
Evaluation of AI Cost Prediction Model to Enroll Patients in Complex Care Management Program
RECRUITING · NA
-
RIVER At Home Ketamine Protocols
RECRUITING
-
Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Cancer Survivors
RECRUITING · NA
-
Comparative Effectiveness of IIMR Versus CDSMP
RECRUITING · NA
-
Training Community Members to be Coaches to Deliver the HealthyLifetime Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI